

Soundbytes

11 March 2004 | News



p ALIGN="left">

Dr Takashi Yohkaichiya

President, Japanese Association of Pharmaceutical Medicine & Sr Executive VP & Chief Medical Officer, Shin Nippon Biomedical Laboratories Ltd, Japan

This is the first time I have come to India. I am very impressed with what I have seen. I am looking at the possibility of putting up a facility here.

Dr Anwar Nasim

Advisor Science, COMSTECH Secretariat, Pakistan

Pakistan is not as strong as India in vaccines. I see a lot of collaboration potential in this area between the two countries.

G Michael Alder

MD, Redmont Venture Partners Inc & Executive Director Biotechnology Association of Alabama, USA

My perception of India has changed considerably after coming here. I no longer see India as I see Thailand, Malaysia, China or any other SouthEast Asian country.

Dr Santosh K Mishra

Executive Director, Bioinformatics Institute, Singapore

India has a great strength in IT and making huge strides in bioinformatics is just the next logical step.

Govindaluri Anand

Associate Director, Investments, Temasek Holdings, Singapore

We are already investors in some of the companies here and I am scouting for more investment opportunities. I see a lot of potential in Hyderabad in the pharma biotech.

Dr Pravin Kini

MD & CSO, CytoGenomics Inc, Chesterfield, USA

It is a good platform for networking except that three-days is a way too long for any event. It should be a one-day event.

Dr Krishna Menon

COO, Kard Scientific, Cambridge, USA

I am glad that I am here. It has been a very productive event in terms of networking and getting to know the biotechnology industry in India.

Dr Vasudeo Ginde

MD, iGate Clinical Research International, Mumbai, India

I would say we need to be extremely quality conscious while taking advantage of this big opportunity of clinical trials. The cost of failing on that count will be very high. Let us not fail even once.

